Breakthrough cancer medicine and its impact on novel drug development in China: report of the US Chinese Anti-Cancer Association (USCACA) and Chinese Society of Clinical Oncology (CSCO) Joint Session at the 17th CSCO Annual Meeting / 癌症
Chinese Journal of Cancer
;
(12): 620-624, 2014.
Article
in English
| WPRIM
| ID: wpr-349624
ABSTRACT
The US Chinese Anti-Cancer Association (USCACA) teamed up with Chinese Society of Clinical Oncology (CSCO) to host a joint session at the17th CSCO Annual Meeting on September 20th, 2014 in Xiamen, China. With a focus on breakthrough cancer medicines, the session featured innovative approaches to evaluate breakthrough agents and established a platform to interactively share successful experiences from case studies of 6 novel agents from both the United States and China. The goal of the session is to inspire scientific and practical considerations for clinical trial design and strategy to expedite cancer drug development in China. A panel discussion further provided in-depth advice on advancing both early and full development of novel cancer medicines in China.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Societies, Medical
/
United States
/
China
/
Drug Discovery
/
Medical Oncology
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Qualitative research
Limits:
Humans
Country/Region as subject:
North America
/
Asia
Language:
English
Journal:
Chinese Journal of Cancer
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS